

---

## Appendix 1: Diagnoses and rates of selected STIs seen at GUM clinics in Northern Ireland: 2000 - 2005

---

### Notes on using these tables:

Diagnoses are calculated based on genitourinary medicine (GUM) clinics in Northern Ireland  
Rates are calculated for the resident population of Northern Ireland

### Data Sources:

Data in these tables are derived from statistical returns compiled at GUM clinics on the KC60 form.

### Definitions of selected conditions presented:

Chlamydia	uncomplicated genital chlamydial infection, KC60 code C4A,C4C
Gonorrhoea	uncomplicated gonorrhoea, KC60 code B1,B2
Syphilis	primary and secondary infectious syphilis, KC60 code A1,A2
Herpes	anogenital herpes (first attack), KC60 code C10A
Warts	anogenital warts (first attack), KC60 code C11A
Total diagnoses	all diagnoses made, includes all A, B, C and E KC60 codes
Total workload	all workload not requiring a diagnosis, includes all D, P and S KC60 codes

### Prepared by:

Communicable Disease Surveillance Centre (NI)  
McBrien Building  
Belfast City Hospital  
Lisburn Road  
Belfast BT9 7AB  
Northern Ireland

Tel. 028-9026-3765  
Email: [cdscni@hpa.org.uk](mailto:cdscni@hpa.org.uk)  
Website: [www.cdscni.org.uk](http://www.cdscni.org.uk)

---



Appendix 1a:

Numbers of new selected diagnoses  
by sex and age group, Northern Ireland, 2000 - 2005

	2000			2001			2002			2003			2004			2005			
	M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total	
Chlamydia	<16	0	6	6	0	6	6	0	7	7	0	7	7	0	13	13	0	9	9
	16-19	50	118	168	47	149	196	44	136	180	81	180	261	72	206	278	75	215	290
	20-24	154	200	354	174	177	351	228	304	532	248	294	542	326	333	659	334	396	730
	25-34	214	130	344	192	117	309	209	147	356	236	151	387	247	159	406	303	184	487
	35-44	54	22	76	47	17	64	58	24	82	60	26	86	46	32	78	54	38	92
	45+	8	7	15	13	8	21	9	4	13	20	5	25	12	7	19	17	6	23
	<b>Total</b>	<b>480</b>	<b>483</b>	<b>963</b>	<b>473</b>	<b>474</b>	<b>947</b>	<b>548</b>	<b>622</b>	<b>1,170</b>	<b>645</b>	<b>663</b>	<b>1,308</b>	<b>703</b>	<b>750</b>	<b>1,453</b>	<b>783</b>	<b>848</b>	<b>1,631</b>
% in MSM	2%			3%			2%			4%			4%			7%			
Gonorrhoea	<16	1	3	4	0	0	0	0	2	2	0	0	0	0	1	1	0	0	0
	16-19	18	10	28	22	7	29	7	0	7	8	8	16	17	8	25	14	3	17
	20-24	31	5	36	34	3	37	36	3	39	45	10	55	32	5	37	47	13	60
	25-34	45	4	49	42	10	52	45	6	51	42	6	48	46	3	49	56	2	58
	35-44	20	2	22	23	1	24	14	0	14	26	2	28	9	1	10	37	1	38
	45+	4	0	4	6	0	6	4	0	4	6	1	7	1	1	2	8	1	9
	<b>Total</b>	<b>119</b>	<b>24</b>	<b>143</b>	<b>127</b>	<b>21</b>	<b>148</b>	<b>106</b>	<b>11</b>	<b>117</b>	<b>127</b>	<b>27</b>	<b>154</b>	<b>105</b>	<b>19</b>	<b>124</b>	<b>162</b>	<b>20</b>	<b>182</b>
% in MSM	9%			18%			11%			31%			23%			40%			
Syphilis	<16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16-19	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0	1
	20-24	0	0	0	0	1	1	3	0	3	2	0	2	5	5	10	5	0	5
	25-34	0	0	0	5	1	6	1	0	1	5	0	5	8	3	11	6	3	9
	35-44	0	0	0	3	0	3	5	0	5	1	0	1	13	2	15	12	0	12
	45+	0	0	0	1	0	1	9	0	9	2	0	2	5	0	5	5	2	7
	<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>9</b>	<b>2</b>	<b>11</b>	<b>19</b>	<b>0</b>	<b>19</b>	<b>10</b>	<b>0</b>	<b>10</b>	<b>31</b>	<b>10</b>	<b>41</b>	<b>29</b>	<b>5</b>	<b>34</b>
% in MSM	0%			89%			47%			50%			68%			66%			
Herpes	<16	0	2	2	0	1	1	0	5	5	1	3	4	0	1	1	0	1	1
	16-19	7	40	47	6	40	46	3	37	40	5	31	36	2	32	34	6	39	45
	20-24	29	52	81	15	48	63	20	54	74	14	53	67	28	56	84	20	64	84
	25-34	47	45	92	39	47	86	35	48	83	23	49	72	25	39	64	28	46	74
	35-44	14	25	39	24	22	46	16	22	38	14	21	35	11	22	33	8	19	27
	45+	11	9	20	9	7	16	5	14	19	3	9	12	3	3	6	4	3	7
	<b>Total</b>	<b>108</b>	<b>173</b>	<b>281</b>	<b>93</b>	<b>165</b>	<b>258</b>	<b>79</b>	<b>180</b>	<b>259</b>	<b>60</b>	<b>166</b>	<b>226</b>	<b>69</b>	<b>153</b>	<b>222</b>	<b>66</b>	<b>172</b>	<b>238</b>
% in MSM	3%			3%			1%			5%			7%			8%			
Warts	<16	5	7	12	2	7	9	1	5	6	4	5	9	0	9	9	0	6	6
	16-19	93	236	329	95	229	324	84	243	327	115	235	350	86	259	345	103	267	370
	20-24	417	366	783	393	358	751	409	357	766	401	411	812	397	358	755	460	403	863
	25-34	429	287	716	422	297	719	458	298	756	386	287	673	387	278	665	443	296	739
	35-44	118	78	196	132	95	227	138	95	233	149	91	240	133	110	243	150	89	239
	45+	56	25	81	63	37	100	57	31	88	56	36	92	56	28	84	52	37	89
	<b>Total</b>	<b>1,118</b>	<b>999</b>	<b>2,117</b>	<b>1,107</b>	<b>1,023</b>	<b>2,130</b>	<b>1,147</b>	<b>1,029</b>	<b>2,176</b>	<b>1,111</b>	<b>1,065</b>	<b>2,176</b>	<b>1,059</b>	<b>1,042</b>	<b>2,101</b>	<b>1,208</b>	<b>1,098</b>	<b>2,306</b>
% in MSM	2%			3%			2%			2%			3%			3%			
<b>Total diagnoses</b>	<b>6,141</b>	<b>5,031</b>	<b>11,172</b>	<b>6,048</b>	<b>5,252</b>	<b>11,300</b>	<b>6,185</b>	<b>5,682</b>	<b>11,867</b>	<b>5,823</b>	<b>5,727</b>	<b>11,550</b>	<b>5,723</b>	<b>5,784</b>	<b>11,507</b>	<b>6,316</b>	<b>6,531</b>	<b>12,847</b>	
<b>Total workload</b>	<b>3,658</b>	<b>2,872</b>	<b>6,530</b>	<b>4,435</b>	<b>3,451</b>	<b>7,886</b>	<b>5,128</b>	<b>3,616</b>	<b>8,744</b>	<b>7,188</b>	<b>6,021</b>	<b>13,209</b>	<b>7,327</b>	<b>7,056</b>	<b>14,383</b>	<b>9,302</b>	<b>7,542</b>	<b>16,844</b>	

Notes on using these tables:

'% in MSM' represents the proportion of the total male diagnoses attributed to men who have sex with men (MSM)

The increased workload in 2003 could be partly due to changes in the reporting system (the addition of S codes)

Definitions of selected conditions:

Chlamydia	uncomplicated genital chlamydial infection, KC60 code C4A,C4C
Gonorrhoea	uncomplicated gonorrhoea, KC60 code B1,B2
Syphilis	primary and secondary infectious syphilis, KC60 code A1,A2
Herpes	anogenital herpes (first attack), KC60 code C10A
Warts	anogenital warts (first attack), KC60 code C11A
Total diagnoses	all diagnoses made (all A, B, C and E KC60 codes)
Total workload	all workload not requiring a diagnosis (D, P and S KC60 codes)

Appendix 1b:

Rates of new selected diagnoses  
by sex and age group, Northern Ireland, per 100,000 population, 2000 - 2005



2000			2001			2002			2003			2004			2005			
M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total	
0.0	15.1	7.4	0.0	15.2	7.4	0.0	17.9	8.7	0.0	18.1	8.8	0.0	33.9	16.5	0.0	23.6	11.5	<16
98.2	236.6	166.6	90.2	294.3	190.7	81.8	264.7	171.1	148.3	347.8	245.4	131.3	398.1	260.8	137.4	417.4	273.3	16-19
281.0	366.5	323.7	313.2	322.8	318.0	407.5	554.7	480.3	430.7	532.4	480.5	548.6	582.5	565.2	541.1	669.1	603.8	20-24
175.0	104.1	139.1	160.1	95.2	127.3	178.1	122.1	149.8	205.4	128.2	166.3	219.2	137.0	177.5	268.4	159.6	213.4	25-34
45.2	17.8	31.2	38.7	13.4	25.8	47.0	18.7	32.6	48.2	20.1	33.9	36.7	24.5	30.5	42.8	29.0	35.7	35-44
3.0	2.2	2.6	4.8	2.5	3.6	3.3	1.2	2.2	7.1	1.5	4.1	4.2	2.1	3.1	5.8	1.8	3.6	45+
58.5	56.0	57.2	57.4	54.8	56.1	66.1	71.7	69.0	77.4	76.2	76.8	84.0	85.8	85.0	92.7	96.3	94.6	Total
2.4	7.6	4.9	0.0	0.0	0.0	0.0	5.1	2.5	0.0	0.0	0.0	0.0	2.6	1.3	0.0	0.0	0.0	<16
35.3	20.0	27.8	42.2	13.8	28.2	13.0	0.0	6.7	14.6	15.5	15.0	31.0	15.5	23.5	25.6	5.8	16.0	16-19
56.6	9.2	32.9	61.2	5.5	33.5	64.3	5.5	35.2	78.2	18.1	48.8	53.8	8.7	31.7	76.1	22.0	49.6	20-24
36.8	3.2	19.8	35.0	8.1	21.4	38.3	5.0	21.5	36.6	5.1	20.6	40.8	2.6	21.4	49.6	1.7	25.4	25-34
16.8	1.6	9.0	18.9	0.8	9.7	11.4	0.0	5.6	20.9	1.5	11.0	7.2	0.8	3.9	29.3	0.8	14.8	35-44
1.5	0.0	0.7	2.2	0.0	1.0	1.4	0.0	0.7	2.1	0.3	1.1	0.3	0.3	0.3	2.7	0.3	1.4	45+
14.5	2.8	8.5	15.4	2.4	8.8	12.8	1.3	6.9	15.2	3.1	9.0	12.6	2.2	7.3	19.2	2.3	10.6	Total
0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	<16
0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.9	16-19
0.0	0.0	0.0	0.0	1.8	0.9	5.4	0.0	2.7	3.5	0.0	1.8	8.4	8.7	8.6	8.1	0.0	4.1	20-24
0.0	0.0	0.0	4.2	0.8	2.5	0.9	0.0	0.4	4.4	0.0	2.1	7.1	2.6	4.8	5.3	2.6	3.9	25-34
0.0	0.0	0.0	2.5	0.0	1.2	4.1	0.0	2.0	0.8	0.0	0.4	10.4	1.5	5.9	9.5	0.0	4.7	35-44
0.0	0.0	0.0	0.4	0.0	0.2	3.3	0.0	1.5	0.7	0.0	0.3	1.7	0.0	0.8	1.7	0.6	1.1	45+
0.0	0.0	0.0	1.1	0.2	0.7	2.3	0.0	1.1	1.2	0.0	0.6	3.7	1.1	2.4	3.4	0.6	2.0	Total
0.0	5.0	2.5	0.0	2.5	1.2	0.0	12.8	6.2	2.5	7.7	5.0	0.0	2.6	1.3	0.0	2.6	1.3	<16
13.7	80.2	46.6	11.5	79.0	44.8	5.6	72.0	38.0	9.2	59.9	33.8	3.6	61.8	31.9	11.0	75.7	42.4	16-19
52.9	95.3	74.1	27.0	87.5	57.1	35.7	98.5	66.8	24.3	96.0	59.4	47.1	98.0	72.0	32.4	108.1	69.5	20-24
38.4	36.0	37.2	32.5	38.2	35.4	29.8	39.9	34.9	20.0	41.6	30.9	22.2	33.6	28.0	24.8	39.9	32.4	25-34
11.7	20.2	16.0	19.7	17.4	18.5	13.0	17.2	15.1	11.3	16.3	13.8	8.8	16.9	12.9	6.3	14.5	10.5	35-44
4.1	2.9	3.5	3.3	2.2	2.7	1.8	4.4	3.2	1.1	2.8	2.0	1.0	0.9	1.0	1.4	0.9	1.1	45+
13.2	20.1	16.7	11.3	19.1	15.3	9.5	20.7	15.3	7.2	19.1	13.3	8.2	17.5	13.0	7.8	19.5	13.8	Total
12.0	17.7	14.8	4.8	17.7	11.1	2.4	12.8	7.5	9.8	12.9	11.3	0.0	23.4	11.4	0.0	15.7	7.7	<16
182.6	473.1	326.3	182.2	452.3	315.3	156.1	472.9	310.9	210.6	454.1	329.1	156.8	500.5	323.7	188.7	518.4	348.7	16-19
761.0	670.6	715.9	707.4	652.9	680.3	730.9	651.4	691.6	696.5	744.2	719.8	668.0	626.2	647.5	745.2	681.0	713.8	20-24
350.8	229.7	289.6	351.9	241.7	296.1	390.3	247.6	318.0	335.9	243.6	289.2	343.4	239.5	290.7	392.5	256.7	323.9	25-34
98.9	63.0	80.6	108.6	75.1	91.5	111.9	74.1	92.7	119.8	70.4	94.2	106.2	84.4	95.0	118.8	67.8	92.8	35-44
21.0	8.0	14.0	23.2	11.7	17.0	20.6	9.6	14.7	19.9	11.0	15.1	19.5	8.4	13.6	17.7	11.0	14.1	45+
136.3	115.8	125.8	134.3	118.3	126.1	138.4	118.6	128.3	133.4	122.4	127.8	126.6	119.2	122.8	143.1	124.8	133.7	Total

Notes on using these tables:

Diagnoses are calculated based on GUM clinics in Northern Ireland, rates are calculated for Northern Ireland's resident population  
Diagnostic rates for specific age groups were estimated by dividing the annual number of diagnoses in each age bracket by the estimated mid-year resident population of Northern Ireland for each age group. The denominators used to calculate rates in people under 16 and over 44 years of age were the population aged 13 to 15, and the population aged over 44 years respectively. The total population was used for the calculation of overall rates.

---

## Appendix 2: All new diagnoses made at GUM clinics in Northern Ireland: 2000 - 2005

---

**Notes on using these tables:**

Diagnoses are calculated based on genitourinary medicine (GUM) clinics in Northern Ireland

**Data Source:**

Data in these tables are derived from statistical returns compiled at GUM clinics on the KC60 form.

**Definitions of selected conditions selected:**

Total diagnoses	all diagnoses made, includes all A, B, C and E KC60 codes
Total workload	all workload not requiring a diagnosis, includes all D, P and S KC60 codes

**Prepared by:**

Communicable Disease Surveillance Centre (NI)  
McBrien Building  
Belfast City Hospital  
Lisburn Road  
Belfast BT9 7AB  
Northern Ireland

Tel. 028-9026-3765  
Email: [cdscni@hpa.org.uk](mailto:cdscni@hpa.org.uk)  
Website: [www.cdscni.org.uk](http://www.cdscni.org.uk)

---

Diagnoses			2000	2001	2002	2003	2004	2005
A1,A2	Primary and secondary infectious syphilis	Male (all)	0	9	19	10	31	29
		-of which MSM	0	8	9	5	21	19
		Female	0	2	0	0	10	5
		<b>Total</b>	<b>0</b>	<b>11</b>	<b>19</b>	<b>10</b>	<b>41</b>	<b>34</b>
A3	Early latent syphilis (first 2 years)	Male (all)	1	1	1	4	1	8
		-of which MSM	1	1	1	4	1	6
		Female	0	1	1	1	2	6
		<b>Total</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>5</b>	<b>3</b>	<b>14</b>
A4,A5,A6	Other acquired syphilis	Male (all)	4	2	2	4	5	20
		-of which MSM	2	0	0	1	1	2
		Female	0	1	1	4	8	17
		<b>Total</b>	<b>4</b>	<b>3</b>	<b>3</b>	<b>8</b>	<b>13</b>	<b>37</b>
A7	Congenital syphilis, aged under 2	Male (all)	0	0	0	0	0	0
		-of which MSM	-	-	-	-	-	-
		Female	0	0	0	0	0	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
A8	Congenital syphilis, aged 2 or over	Male (all)	0	1	0	0	1	0
		-of which MSM	-	-	-	-	-	-
		Female	0	0	0	0	1	1
		<b>Total</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>1</b>
A9	Epidemiological treatment of suspected syphilis	Male (all)	1	3	3	1	7	1
		-of which MSM	0	2	2	0	2	0
		Female	0	0	0	1	1	0
		<b>Total</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>2</b>	<b>8</b>	<b>1</b>
B1,B2	Uncomplicated gonorrhoea	Male (all)	119	127	106	127	105	162
		-of which MSM	11	23	12	39	24	64
		Female	24	21	11	27	19	20
		<b>Total</b>	<b>143</b>	<b>148</b>	<b>117</b>	<b>154</b>	<b>124</b>	<b>182</b>
B3	Gonococcal ophthalmia neonatorum	Male (all)	0	0	0	2	0	2
		-of which MSM	-	-	-	-	-	-
		Female	0	0	1	1	1	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>3</b>	<b>1</b>	<b>2</b>
B4	Epidemiological treatment of suspected gonorrhoea	Male (all)	14	19	13	15	12	38
		-of which MSM	2	8	5	8	2	15
		Female	19	29	20	18	20	53
		<b>Total</b>	<b>33</b>	<b>48</b>	<b>33</b>	<b>33</b>	<b>32</b>	<b>91</b>
B5	Gonococcal complications	Male (all)	3	2	2	3	0	0
		-of which MSM	0	0	1	1	0	0
		Female	2	0	1	0	2	2
		<b>Total</b>	<b>5</b>	<b>2</b>	<b>3</b>	<b>3</b>	<b>2</b>	<b>2</b>

**Northern Ireland: Number of new diagnoses by sex, 2000 - 2005 continued**

Diagnoses			2000	2001	2002	2003	2004	2005
C1,C2,C3	Chancroid/LGV/Donovanosis	Male (all)	0	0	1	1	1	0
		-of which MSM	-	-	-	-	-	-
		Female	0	0	0	3	17	7
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>4</b>	<b>18</b>	<b>7</b>
C4A,C4C	Uncomplicated genital chlamydial infection	Male (all)	480	473	548	645	703	783
		-of which MSM	8	13	10	27	30	52
		Female	483	474	622	663	750	848
		<b>Total</b>	<b>963</b>	<b>947</b>	<b>1,170</b>	<b>1,308</b>	<b>1,453</b>	<b>1,631</b>
C4B	Complicated genital chlamydial infection	Male (all)	6	10	12	9	9	20
		-of which MSM	0	1	1	0	0	0
		Female	34	32	28	26	57	62
		<b>Total</b>	<b>40</b>	<b>42</b>	<b>40</b>	<b>35</b>	<b>66</b>	<b>82</b>
C4D	Chlamydial ophthalmia neonatorum	Male (all)	1	0	2	4	7	5
		-of which MSM	-	-	-	-	-	-
		Female	2	1	1	1	7	0
		<b>Total</b>	<b>3</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>14</b>	<b>5</b>
C4E	Epidemiological treatment of suspected genital chlamydial infection	Male (all)	128	163	165	220	243	356
		-of which MSM	3	3	6	5	7	7
		Female	163	147	174	248	284	321
		<b>Total</b>	<b>291</b>	<b>310</b>	<b>339</b>	<b>468</b>	<b>527</b>	<b>677</b>
C4H*	Uncomplicated non-gonococcal/non-spec urethritis males(females) treatment of mucopurulent cervicitis	Male (all)	1,891	1,674	1,731	1,692	2,074	1,898
		-of which MSM	66	79	112	73	106	114
		Female	0	0	0	148	95	138
		<b>Total</b>	<b>1,891</b>	<b>1,674</b>	<b>1,731</b>	<b>1,840</b>	<b>2,169</b>	<b>2,036</b>
C4I	Epidemiological treatment of NSGI	Male (all)	51	122	56	46	53	68
		-of which MSM	2	5	10	3	5	6
		Female	637	591	624	497	718	640
		<b>Total</b>	<b>688</b>	<b>713</b>	<b>680</b>	<b>543</b>	<b>771</b>	<b>708</b>
C5	Complicated non-gonococcal/non-specific infection	Male (all)	79	80	71	65	46	63
		-of which MSM	2	2	8	4	2	2
		Female	97	89	144	91	121	146
		<b>Total</b>	<b>176</b>	<b>169</b>	<b>215</b>	<b>156</b>	<b>167</b>	<b>209</b>
C6A	Trichomoniasis	Male (all)	1	2	5	3	3	4
		-of which MSM	-	-	-	-	-	-
		Female	25	25	35	22	36	31
		<b>Total</b>	<b>26</b>	<b>27</b>	<b>40</b>	<b>25</b>	<b>39</b>	<b>35</b>
C6B	Anaerobic/bacterial vaginosis & male infection	Male (all)	114	118	64	45	52	50
		-of which MSM	-	-	-	-	-	-
		Female	852	998	1,128	1,176	1,112	1,323
		<b>Total</b>	<b>966</b>	<b>1,116</b>	<b>1,192</b>	<b>1,221</b>	<b>1,164</b>	<b>1,373</b>
C6C	Other vaginosis/vaginitis/balanitis	Male (all)	100	181	257	148	104	170
		-of which MSM	-	-	-	-	-	-
		Female	54	72	75	121	108	111
		<b>Total</b>	<b>154</b>	<b>253</b>	<b>332</b>	<b>269</b>	<b>212</b>	<b>281</b>

**Northern Ireland: Number of new diagnoses by sex, 2000 - 2005 continued**

Diagnoses			2000	2001	2002	2003	2004	2005
C7A	Genital candidosis	Male (all)	615	693	686	567	388	458
		-of which MSM	-	-	-	-	-	-
		Female	975	1,082	1,123	897	698	868
		<b>Total</b>	<b>1,590</b>	<b>1,775</b>	<b>1,809</b>	<b>1,464</b>	<b>1,086</b>	<b>1,326</b>
C7B	Epidemiological treatment of C6 & C7	Male (all)	4	8	16	7	23	4
		-of which MSM	-	-	-	-	-	-
		Female	9	5	9	10	27	12
		<b>Total</b>	<b>13</b>	<b>13</b>	<b>25</b>	<b>17</b>	<b>50</b>	<b>16</b>
C8,C9	Scabies/pediculosis pubis	Male (all)	147	118	170	106	69	47
		-of which MSM	13	14	25	17	9	4
		Female	62	47	52	34	21	8
		<b>Total</b>	<b>209</b>	<b>165</b>	<b>222</b>	<b>140</b>	<b>90</b>	<b>55</b>
C10A	Genital herpes simplex – first attack	Male (all)	108	93	79	60	69	66
		-of which MSM	3	3	1	3	5	5
		Female	173	165	180	166	153	172
		<b>Total</b>	<b>281</b>	<b>258</b>	<b>259</b>	<b>226</b>	<b>222</b>	<b>238</b>
C10B	Genital herpes simplex – recurrence	Male (all)	64	81	60	48	33	49
		-of which MSM	2	4	6	1	3	4
		Female	66	95	78	85	73	79
		<b>Total</b>	<b>130</b>	<b>176</b>	<b>138</b>	<b>133</b>	<b>106</b>	<b>128</b>
C11A	Genital warts – first attack	Male (all)	1,118	1,107	1,147	1,111	1,059	1,208
		-of which MSM	22	28	28	23	36	40
		Female	999	1,023	1,029	1,065	1,042	1,098
		<b>Total</b>	<b>2,117</b>	<b>2,130</b>	<b>2,176</b>	<b>2,176</b>	<b>2,101</b>	<b>2,306</b>
C11B	Genital warts – recurrence	Male (all)	635	460	462	407	320	465
		-of which MSM	18	10	12	12	9	13
		Female	185	204	198	256	233	360
		<b>Total</b>	<b>820</b>	<b>664</b>	<b>660</b>	<b>663</b>	<b>553</b>	<b>825</b>
C11C	Genital warts – re-registered cases <sup>†</sup>	Male (all)	67	107	121	75	83	52
		-of which MSM	-	-	-	-	-	-
		Female	26	30	45	35	66	54
		<b>Total</b>	<b>93</b>	<b>137</b>	<b>166</b>	<b>110</b>	<b>149</b>	<b>106</b>
C12	Molluscum contagiosum	Male (all)	75	83	90	94	84	117
		-of which MSM	1	5	5	3	2	3
		Female	52	36	47	48	48	61
		<b>Total</b>	<b>127</b>	<b>119</b>	<b>137</b>	<b>142</b>	<b>132</b>	<b>178</b>
C13	Antigen positive viral hepatitis B	Male (all)	3	3	3	1	-	-
		-of which MSM	0	1	0	0	-	-
		Female	1	1	1	0	-	-
		<b>Total</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>1</b>	-	-
C13A*	Viral hepatitis B (HbsAg positive): first diagnosis**	Male (all)	-	-	-	5	6	3
		-of which MSM	-	-	-	1	1	0
		Female	-	-	-	0	1	0
		<b>Total</b>	-	-	-	<b>5</b>	<b>7</b>	<b>3</b>

Northern Ireland: Number of new diagnoses by sex, 2000 - 2005 continued

Diagnoses		2000	2001	2002	2003	2004	2005	
C13B*	**number of which were acute viral hepatitis B	Male (all)	-	-	-	0	1	2
		-of which MSM	-	-	-	0	0	0
		Female	-	-	-	0	0	1
		<b>Total</b>	-	-	-	<b>0</b>	<b>1</b>	<b>3</b>
C13C*	Viral hepatitis B: subsequent presentation	Male (all)	-	-	-	3	1	2
		-of which MSM	-	-	-	0	0	0
		Female	-	-	-	0	0	0
		<b>Total</b>	-	-	-	<b>3</b>	<b>1</b>	<b>2</b>
C14*	Viral hepatitis C: first diagnosis (previous to 2003 C14 was other viral hepatitis)	Male (all)	4	3	1	4	1	4
		-of which MSM	0	0	0	0	0	1
		Female	0	0	1	0	0	2
		<b>Total</b>	<b>4</b>	<b>3</b>	<b>2</b>	<b>4</b>	<b>1</b>	<b>6</b>
E1A	Asymptomatic HIV infection – first presentation	Male (all)	5	8	9	15	12	15
		-of which MSM	2	2	2	2	6	6
		Female	6	5	3	2	6	14
		<b>Total</b>	<b>11</b>	<b>13</b>	<b>12</b>	<b>17</b>	<b>18</b>	<b>29</b>
E1B*	Asymptomatic HIV infection – subsequent presentation	Male (all)	99	86	90	43	-	-
		-of which MSM	0	0	0	0	-	-
		Female	25	13	14	6	-	-
		<b>Total</b>	<b>124</b>	<b>99</b>	<b>104</b>	<b>49</b>	-	-
E1BE2B*	Subsequent HIV presentation (not AIDS)	Male (all)	-	-	-	139	90	122
		-of which MSM	-	-	-	-	-	-
		Female	-	-	-	46	31	66
		<b>Total</b>	-	-	-	<b>185</b>	<b>121</b>	<b>188</b>
E2A	HIV infection with symptoms, not AIDS – first presentation	Male (all)	11	5	2	6	6	5
		-of which MSM	4	4	1	2	2	3
		Female	2	3	0	1	6	4
		<b>Total</b>	<b>13</b>	<b>8</b>	<b>2</b>	<b>7</b>	<b>12</b>	<b>9</b>
E2B*	HIV infection with symptoms, not AIDS – subsequent presentation	Male (all)	72	68	54	4	-	-
		-of which MSM	0	0	0	0	-	-
		Female	20	12	10	0	-	-
		<b>Total</b>	<b>92</b>	<b>80</b>	<b>64</b>	<b>4</b>	-	-
E3A*	AIDS – first presentation	Male (all)	8	2	9	2	-	-
		-of which MSM	4	1	7	0	-	-
		Female	0	2	1	0	-	-
		<b>Total</b>	<b>8</b>	<b>4</b>	<b>10</b>	<b>2</b>	-	-
E3A1*	AIDS: first presentation - new HIV diagnosis	Male (all)	-	-	-	2	0	2
		-of which MSM	-	-	-	2	0	1
		Female	-	-	-	1	2	0
		<b>Total</b>	-	-	-	<b>3</b>	<b>2</b>	<b>2</b>
E3A2*	AIDS: first presentation - HIV diagnosed previously	Male (all)	-	-	-	4	3	1
		-of which MSM	-	-	-	3	2	1
		Female	-	-	-	0	0	0
		<b>Total</b>	-	-	-	<b>4</b>	<b>3</b>	<b>1</b>

**Northern Ireland: Number of new diagnoses by sex, 2000 - 2005 continued**

Diagnoses			2000	2001	2002	2003	2004	2005
E3B	AIDS – subsequent presentation	Male (all)	113	136	128	76	18	17
		-of which MSM	-	-	-	-	-	-
		Female	38	46	25	27	8	1
		<b>Total</b>	<b>151</b>	<b>182</b>	<b>153</b>	<b>103</b>	<b>26</b>	<b>18</b>
<b>Total diagnoses</b>								
	Male (all)	6,141	6,048	6,185	5,823	5,723	6,316	
	-of which MSM	166	217	264	239	276	368	
	Female	5,031	5,252	5,682	5,727	5,784	6,531	
	<b>Total</b>	<b>11,172</b>	<b>11,300</b>	<b>11,867</b>	<b>11,550</b>	<b>11,507</b>	<b>12,847</b>	
<b>Workload</b>								
D2A	Urinary tract infection	Male (all)	43	58	43	50	29	27
		-of which MSM	-	-	-	-	-	-
		Female	95	71	84	39	36	41
		<b>Total</b>	<b>138</b>	<b>129</b>	<b>127</b>	<b>89</b>	<b>65</b>	<b>68</b>
D2B	Other conditions requiring treatment at GUM clinic	Male (all)	700	726	786	429	305	370
		-of which MSM	-	-	-	-	-	-
		Female	492	452	494	261	246	241
		<b>Total</b>	<b>1,192</b>	<b>1,178</b>	<b>1,280</b>	<b>690</b>	<b>551</b>	<b>611</b>
D3	Other episodes not requiring treatment	Male (all)	1,932	2,430	2,959	1,685	1,146	1,327
		-of which MSM	-	-	-	-	-	-
		Female	1,513	1,987	2,210	1,370	1,073	930
		<b>Total</b>	<b>3,445</b>	<b>4,417</b>	<b>5,169</b>	<b>3,055</b>	<b>2,219</b>	<b>2,257</b>
P1A	HIV antibody counselling - with testing	Male (all)	650	718	893	432	180	151
		-of which MSM	65	107	147	77	18	19
		Female	397	549	545	251	119	124
		<b>Total</b>	<b>1,047</b>	<b>1,267</b>	<b>1,438</b>	<b>683</b>	<b>299</b>	<b>275</b>
P1B	HIV antibody counselling - without testing	Male (all)	162	230	152	58	77	226
		-of which MSM	25	43	24	14	3	9
		Female	94	100	81	85	42	46
		<b>Total</b>	<b>256</b>	<b>330</b>	<b>233</b>	<b>143</b>	<b>119</b>	<b>272</b>
P2	Hepatitis B vaccination	Male (all)	171	273	295	191	161	215
		-of which MSM	61	125	140	97	73	110
		Female	20	41	19	23	16	29
		<b>Total</b>	<b>191</b>	<b>314</b>	<b>314</b>	<b>214</b>	<b>177</b>	<b>244</b>
P3	Family Planning	Male (all)	-	-	-	-	-	-
		-of which MSM	-	-	-	-	-	-
		Female	96	152	81	33	36	24
		<b>Total</b>	<b>96</b>	<b>152</b>	<b>81</b>	<b>33</b>	<b>36</b>	<b>24</b>
P4A	Cervical cytology - minor abnormality	Male (all)	-	-	-	-	-	-
		-of which MSM	-	-	-	-	-	-
		Female	163	98	100	71	25	4
		<b>Total</b>	<b>163</b>	<b>98</b>	<b>100</b>	<b>71</b>	<b>25</b>	<b>4</b>

**Northern Ireland: Number of new diagnoses by sex, 2000 - 2005 continued**

Diagnoses			2000	2001	2002	2003	2004	2005
P4B	Cervical cytology - major abnormality	Male (all)	-	-	-	-	-	-
		-of which MSM	-	-	-	-	-	-
		Female	2	1	2	1	14	0
		<b>Total</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>14</b>	<b>0</b>
S1*	Sexual health screen (no HIV antibody test)	Male (all)	-	-	-	3,210	3,459	2,412
		-of which MSM	-	-	-	77	91	60
		Female	-	-	-	3,135	3,597	2,739
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>6,345</b>	<b>7,056</b>	<b>5,151</b>
S2*	HIV antibody test and sexual health screen	Male (all)	-	-	-	1,133	1,970	4,574
		-of which MSM	-	-	-	101	175	298
		Female	-	-	-	752	1,852	3,364
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,885</b>	<b>3,822</b>	<b>7,938</b>
<b>Total workload</b>	Male (all)		3,658	4,435	5,128	7,188	7,327	9,302
	Female		2,872	3,451	3,616	6,021	7,056	7,542
	<b>Total</b>		<b>6,530</b>	<b>7,886</b>	<b>8,744</b>	<b>13,209</b>	<b>14,383</b>	<b>16,844</b>
<b>Total diagnoses and workload</b>	Male (all)		9,799	10,483	11,313	13,011	13,050	15,618
	Female		7,903	8,703	9,298	11,748	12,840	14,073
	<b>Total</b>		<b>17,702</b>	<b>19,186</b>	<b>20,611</b>	<b>24,759</b>	<b>25,890</b>	<b>29,691</b>

\* KC60 codes were created/revised in quarter 3, 2002

† previous diagnosis of C11A or C11B treated for more than 3 months

- data not available/applicable